We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Vitamin B6 requirements and recommendations.
The principal metabolic function of vitamin B6 is in amino acid metabolism, although the greater part of the body's vitamin B6 is in muscle, associated with glycogen phosphorylase, and the vitamin also has an important role in the actions of steroid hormones. It is usual to calculate vitamin B6 requirements relative to protein intake. An adequate intake to meet the requirements of virtually the whole population is generally considered to be 15 micrograms/g dietary protein. This is the basis of RDAs in most countries, although differences of interpretation and application of the experimental data result in widely differing recommendations from different authorities. Current RDAs range between 1.5 and 2.2 mg/d. A minimum safe intake, below which an individual would have a high probability of deficiency, is 11 micrograms/g dietary protein. Higher intakes are required in pregnancy and lactation (although there are problems in determining the requirement of the infant), and possibly also in the elderly. Average intakes of vitamin B6 in developed countries meet the target of 15 micrograms/g dietary protein, although there is biochemical evidence of inadequate vitamin B6 nutritional status in 10-25 per cent of the population. It is not know whether this has any clinical significance; it is unlikely that normal patterns of food intake would permit a significantly greater average intake of the vitamins without fortification or the use of supplements. There is little evidence that pharmacological doses of vitamin B6 have any beneficial effect. Neurological damage has been reported at extremely high intakes (in excess of 500 mg/d), and even more modest doses (50-100 mg/d) cannot be regarded as being without hazard.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
The Effect of Albumin Administration in Critically Ill Patients: A Retrospective Single-Center Analysis.Critical Care Medicine 2024 Februrary 8
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app